drugset / Trial / NCT06263348
A Post-Marketing Safety Study of Dorzagliatin in Patients With Type 2 Diabetes
Phase 4
Completed
2024 enrolled
Hua Medicine Limited
Kun Tuo Xincheng Pharmaceutical Researchand Development(Beijing)Co.,Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the long-term safety of Dorzagliatin in a larger population of type 2 diabetes mellitus patients by collecting the post-marketing clinical safety data of Dorzagliatin.
Timeline
- Start
- 2024-01-17
- Primary completion
- 2025-12-31
- Completion
- 2026-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dorzagliatin | Small molecule | 75 mg | — |